RESEARCH ARTICLE

Host deficiency in ephrin-A1 inhibits breast cancer metastasis

[version 1; peer review: 3 approved]

Eileen Shiuan ^{1,2}, Ashwin Inala¹, Shan Wang^{3,4}, Wenqiang Song^{3,4},
Victoria Youngblood⁵, Jin Chen^{3,4,6,7}, Dana M. Brantley-Sieders ^{4,6}

¹Program in Cancer Biology, Vanderbilt University, Nashville, TN, 37232, USA

²Medical Scientist Training Program, Vanderbilt University, Nashville, TN, 37232, USA

³Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN, 37212, USA

⁴Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

⁵School of Nursing, Duke University, Durham, NC, 27710, USA

⁶Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA

⁷Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, 37232, USA

V1 First published: 30 Mar 2020, 9:217
<https://doi.org/10.12688/f1000research.22689.1>
 Latest published: 14 May 2020, 9:217
<https://doi.org/10.12688/f1000research.22689.2>

Abstract

Background: The conventional dogma of treating cancer by focusing on the elimination of tumor cells has been recently refined to include consideration of the tumor microenvironment, which includes host stromal cells. Ephrin-A1, a cell surface protein involved in adhesion and migration, has been shown to be tumor suppressive in the context of the cancer cell. However, its role in the host has not been fully investigated. Here, we examine how ephrin-A1 host deficiency affects cancer growth and metastasis in a murine model of breast cancer.

Methods: 4T1 cells were orthotopically implanted into the mammary fat pads or injected into the tail veins of ephrin-A1 wild-type (*Efna1*^{+/+}), heterozygous (*Efna1*^{+/-}), or knockout (*Efna1*^{-/-}) mice. Tumor growth, lung metastasis, and tumor recurrence after surgical resection were measured. Flow cytometry and immunohistochemistry (IHC) were used to analyze various cell populations in primary tumors and tumor-bearing lungs.

Results: While primary tumor growth did not differ between *Efna1*^{+/+}, *Efna1*^{+/-}, and *Efna1*^{-/-} mice, lung metastasis and primary tumor recurrence were significantly decreased in knockout mice. *Efna1*^{-/-} mice had reduced lung colonization of 4T1 cells compared to *Efna1*^{+/+} littermate controls as early as 24 hours after tail vein injection. Furthermore, established lung lesions in *Efna1*^{-/-} mice had reduced proliferation compared to those in *Efna1*^{+/+} controls.

Conclusions: Our studies demonstrate that host deficiency of ephrin-A1 does not impact primary tumor growth but does affect metastasis by providing a less favorable metastatic niche for cancer cell colonization and growth. Elucidating the mechanisms by which host ephrin-A1 impacts cancer relapse and metastasis may shed new light

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 14 May 2020			 view
version 1 30 Mar 2020	 view	 view	 view

1. **Jinming Yang**, University of Kentucky, Lexington, USA

2. **Elena B. Pasquale** , Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA

3. **Nikki Cheng**, University of Kansas Medical Center (KUMC), Kansas City, USA

Any reports and responses or comments on the article can be found at the end of the article.

on novel therapeutic strategies.

Keywords

Ephrin-A1, host-tumor interactions, breast cancer, metastasis, metastatic niche

This article is included in the **Oncology** gateway.

Corresponding author: Dana M. Brantley-Sieders (dana.brantley@vumc.org)

Author roles: **Shiuan E:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Inala A:** Data Curation, Investigation, Resources, Validation, Writing – Review & Editing; **Wang S:** Data Curation, Investigation, Writing – Review & Editing; **Song W:** Data Curation, Investigation, Writing – Review & Editing; **Youngblood V:** Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Writing – Original Draft Preparation, Writing – Review & Editing; **Chen J:** Conceptualization, Resources, Supervision, Writing – Review & Editing; **Brantley-Sieders DM:** Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Validation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by NIH grants T32 GM0734 (ES), F30 CA216891 (ES), T32 HL007751 (VY), F31 CA180407 (VY), R01 CA148934 (DB); R01 CA177681 (JC), and R01 CA95004 (JC), as well as VA Merit Award 5101BX000134 and VA Research Career Scientist Award (JC).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Shiuan E *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Shiuan E, Inala A, Wang S *et al.* **Host deficiency in ephrin-A1 inhibits breast cancer metastasis [version 1; peer review: 3 approved]** F1000Research 2020, 9:217 <https://doi.org/10.12688/f1000research.22689.1>

First published: 30 Mar 2020, 9:217 <https://doi.org/10.12688/f1000research.22689.1>

Introduction

Over the past several decades, the conventional dogma of treating cancer by focusing on the elimination of rapidly dividing tumor cells has been gradually refined to include consideration of the environment in which the tumor thrives – the tumor microenvironment. The tumor microenvironment consists of both cancer cells and host stromal cells, such as endothelial cells, immune populations, and fibroblasts. Prominent discoveries regarding tumor-associated endothelium and immune cells have notably led to breakthrough therapeutic strategies with anti-angiogenic agents and immunotherapies, respectively^{1–4}. Thus, understanding the host-tumor interactions involved in tumor growth and metastasis is critical for the development and application of new anti-cancer therapies.

As a result of new advancements in targeted and immunotherapies, the majority of patients with early stage disease have a very favorable prognosis. However, patients who later develop distant metastasis or who are diagnosed with disseminated disease at the onset are typically very difficult to treat effectively^{5,6}. This is largely because our knowledge of how cancer cells spread is still limited. Cancer metastasis is a dynamic and complex process that requires tumor cells to undergo many steps, including adopting invasive properties, intravasating into proximal vasculature, surviving in circulation, evading immunosurveillance, extravasating from distant vasculature, and finally adapting to selective pressures of a new environment^{7,8}. Each of these steps involves multiple interactions between cancer cells and different types of host stromal cells. As an example, breast cancer most commonly metastasizes to the lung, bone, liver, and brain, but how and why these cells travel and colonize these particular organs is still unknown^{5,6}. A better understanding of how breast cancer metastasizes to these distant sites is greatly needed in order to develop more effective therapies and prevent spread of malignant disease.

Ephrin-A1 is a cell surface protein that regulates cell adhesion and migration^{9–28}, and its role in cancer has recently been investigated in several different solid tumors^{29–35}. It belongs to the group of ephrin ligands that interact with the largest family of receptor tyrosine kinases (RTKs), the Eph receptors, and regulates various developmental processes, such as embryonic cardiovascular development and angiogenic remodeling^{36–38}. It is expressed in various cell types, including epithelial, endothelial, and immune cells and is the primary ligand for EphA2 RTK, which has been implicated in cancer growth and metastasis in various solid tumors^{36–41}. While ephrin-A1 expression in cancer cells has been shown to be tumor suppressive^{25,26,42,43}, its role in the host, has not been fully investigated. Here, we use ephrin-A1 knockout mice to examine how ephrin-A1 host deficiency affects cancer growth and metastasis in a murine model of breast cancer.

To test the impact of ephrin-A1 host deficiency on cancer progression, we utilized an orthotopic 4T1 mammary tumor model, as well as two different models of metastasis. While primary tumor growth did not significantly differ between ephrin-A1 wild-type (*Efnal*^{+/+}), heterozygous (*Efnal*^{+/-}), and knockout

(*Efnal*^{-/-}) mice, metastasis and primary tumor recurrence were significantly decreased in *Efnal*^{-/-} mice. Results of analysis on tumor-infiltrating immune cell populations and vascularity in the primary tumor did not evidently explain the differences in metastasis between *Efnal*^{+/+} and *Efnal*^{-/-} mice. However, tumor cell lung colonization was reduced in *Efnal*^{-/-} mice, and lung metastases in *Efnal*^{-/-} mice were less proliferative than in their wild-type counterparts, suggesting that the metastatic niche in *Efnal*^{-/-} mice is less hospitable for invading tumor cells. Together, our studies suggest that host deficiency of ephrin-A1 does not impact initial tumor growth but does affect metastasis through inhibiting cancer cell extravasation and proliferation at the metastatic niche.

Methods

Animal models

Animals were housed in a non-barrier animal facility under pathogen-free conditions, 12-hour light/dark cycle, and access to standard rodent diet and water *ad libitum*. Experiments were performed in accordance with AAALAC guidelines and with Vanderbilt University Medical Center Institutional Animal Care and Use Committee approval. All mice used in this study were immunocompetent BALB/c mice. Ephrin-A1 knockout (*Efnal*^{-/-}) mice were previously characterized by our lab⁴⁴. To generate littermate controls, wild-type BALB/c mice were purchased from Jackson Laboratory and mated with *Efnal*^{-/-} mice to generate heterozygote mating pairs. *Efnal*^{+/+}, *Efnal*^{+/-} and *Efnal*^{-/-} animals were identified by PCR analysis of genomic DNA using the following primers: Forward primer (5'-TGGTTATATCCCCCACCTCACAC-3') and two allele-specific reverse primers (WT 5'-AAGGACTCCCATATCTCAGCGACG-3') and (KO 5'-AGACTGCCTTGGGAAAAGCG-3'). Mice were co-housed with one to four littermates for at least two weeks prior to and during all experiments and compared with littermate controls whenever possible. All mice used for tumor experiments were six to ten weeks old at the onset on the experiment. Experimental cohorts were limited to litters that were born within two consecutive weeks and that also had at least one *Efnal*^{-/-} and *Efnal*^{+/+} gender-matched littermate pair and, when applicable, at least one *Efnal*^{+/-} gender-matched littermate. Sample sizes are as shown in the figures and range from three to twelve mice per group. At experimental endpoints, mice were euthanized by cervical dislocation.

Cell culture

4T1 murine mammary adenocarcinoma cells were purchased from ATCC and maintained in DMEM (Corning #MT10013CV) supplemented with penicillin/streptomycin (Gibco #15140163) and 10% FBS (Gibco #A3160502). 4T1-GFP-luciferase clones were generated by serial dilutions of 4T1 cells with lentiviral overexpression of GFP and luciferase genes.

Tumor models

To reflect human breast cancer, only female mice were used for tumor experiments. For orthotopic mammary tumor implantations, 1×10⁵ 4T1 cells suspended in a 1:1 mixture of PBS and Growth Factor-Reduced Matrigel (Corning #354230) were injected through the nipple into the fourth mammary fat pads of

six to eight-week-old female mice. Tumor dimensions were measured by digital caliper at given time points every other day, and volume was calculated using the following formula: volume = length $\times$ width² $\times$ 0.52. To observe spontaneous lung metastases and primary tumor recurrence, mammary tumors were resected at day 14 post-implantation, along with draining inguinal lymph nodes and surrounding fat pads, and mice were ultimately sacrificed at day 32. At the time of surgical resection of primary tumors on day 14, tumors were weighed and cut in half to provide tissue for both flow cytometry analysis and cryosection staining. At the experimental endpoint on day 32, recurrent tumors were weighed, and lung metastases were counted in a blinded manner. For lung colonization experiments, 4T1-GFP-luciferase cells suspended in PBS were injected via tail vein, and mice underwent *in vivo* bioluminescence imaging with a PerkinElmer IVIS Spectrum several hours post-injection to verify successful and equal delivery of 4T1 cells. To observe gradual formation of GFP+ metastases, 1×10^5 4T1-GFP-luciferase cells were injected via tail vein, and mice were sacrificed at day 17. GFP+ lung metastases were counted in a blinded manner. The left lung lobe of each mouse was fixed in 10% formalin for subsequent formalin-fixed paraffin-embedded (FFPE) processing, sectioning, and H&E staining, while the other lung lobes were processed for flow cytometry analysis. To observe early colonization and proliferation of 4T1 cells, 5×10^5 4T1-GFP-luciferase cells labeled with CellTrace Violet dye (Invitrogen #C34571) were injected via tail vein. At 24 hours, mice were sacrificed, and lungs were perfused with PBS and processed for flow cytometry analysis.

Immunohistochemistry (IHC) and Immunofluorescence (IF)

FFPE lung sections were prepared and stained for PCNA (1:100, BD Biosciences #555567 raised in mouse, RRID: AB_395947) as described previously⁴⁵. Slides were blinded, and the number of metastatic foci per section of lobe was quantified. Nuclear PCNA staining was analyzed using ImageJ v1.52o with the IHC Profiler plugin⁴⁶ and percentage of PCNA+ tumor cell nuclei were quantified. Each data point is an average of two sections of the left lung from an individual mouse. To prepare cryosections, mammary tumors were frozen in OCT Compound (Thermo Fisher Scientific #23-730-571) on dry ice and stored at -80°C. Sections (8 μ m) were cut on a Leica Cryostat CM1950, fixed in 4% PFA, washed with PBS, permeabilized with 0.3% Triton X-100 (Sigma-Aldrich #X100), and blocked using M.O.M. Mouse Ig Blocking Reagent and Protein Concentrate (Vector Laboratories #PK-2200) per manufacturer recommendations and with 2.5% goat serum (Sigma-Aldrich #G9023) in PBS. Slides were then incubated over two nights at 4°C with primary antibodies against CD31 (1:150, Biolegend #102501 raised in rat, RRID: AB_312908) and α SMA (1:150, Dako #M085129-2 raised in mouse, RRID: AB_2811108) in blocking buffer. After washing with PBS, slides were incubated for one hour at room temperature in secondary antibodies goat anti-rat Axs594 (1:500, Invitrogen #A11007, RRID: AB_10561522) and anti-mouse Axs488 (1:500, Invitrogen #A11001, RRID: AB_2534069), washed with PBS, and mounted with ProLong Gold Antifade Mountant with DAPI (Invitrogen #P36931). Slides were blinded, and

images were taken by an Olympus DP72 camera through a BX60 inverted fluorescence microscope and processed using CellSens Dimension software. A total of 12–40 20x fields of view were analyzed from each section using ImageJ. For α SMA analysis, images were evaluated for colocalization with CD31 staining, and data was displayed as a percentage of α SMA+ out of CD31+ area or integrated intensity. Each data point is an average of all fields of view of two to three tumor sections from an individual mouse.

Flow cytometry

Tumors and lungs were minced and dissociated in RPMI-1640 media (Corning #MT10040CV) containing 2.5% FBS, 1 mg/ml collagenase 1A (Sigma-Aldrich #C9891), and 0.25 mg/ml DNase I (Sigma-Aldrich #DN25) for 45 minutes at 37°C. Digested tissue was then filtered through a 70- μ m strainer, and red blood cells were lysed using ACK Lysis Buffer (KD Medical #RGF-3015). Samples were washed with PBS and stained with Ghost Dye Violet V510 (Tonbo Biosciences #13-0870) to exclude dead cells. After washing with buffer (0.5% BSA, 2mM EDTA in PBS), samples were blocked in α CD16/32 mouse Fc block (Tonbo Biosciences #70-0161) and stained for extracellular proteins using an antibody master mix made in buffer. After washing with buffer, cells were fixed with 2% PFA. For FoxP3 intracellular staining, cells were permeabilized using the FoxP3 Transcription Factor Staining Kit (Tonbo Biosciences #TNB-0607-KIT) per manufacturer protocol. Flow cytometry data was obtained on a BD 4-laser Fortessa using BD FACS Diva software v8.0.1 and analyzed using FlowJo software v10.6.1. Fluorescence minus one (FMO) samples were used as gating controls when needed. Antibodies used in flow panels are detailed in Table 1, and gating strategies used in analysis are detailed in Table 2. Each data point is generated after analyzing at least 5×10^5 viable cells from a specimen from an individual mouse.

Statistical analysis

All graphs and statistical analysis were completed using GraphPad Prism software v6.07. For comparisons between two groups, an unpaired Mann-Whitney *U*-test was performed. For comparisons between three groups, a Kruskal-Wallis *H*-test was performed, followed by post-hoc Mann-Whitney *U*-tests evaluating differences between the knockout and either the wild-type or heterozygote animals. A *P*-value less than 0.05 was considered statistically significant.

Results

Ephrin-A1-deficient hosts have reduced metastasis *in vivo*

We initially investigated the impact of ephrin-A1 host deficiency on primary tumor growth by implanting 4T1 cells orthotopically into the mammary fat pads of syngeneic BALB/c female *Efnal*^{+/+} and *Efnal*^{-/-} mice. No difference in primary tumor growth or weight at 21 days post-implantation was observed (Figure 1A). To test the impact of ephrin-A1 host deficiency on spontaneous metastasis, 4T1 cells were implanted orthotopically as described above and surgically resected on day 14 post-implantation to allow for gradual development of endogenous metastases by day 32 (Figure 1B). As expected,

Table 1. Antibodies used in flow cytometry analysis.

Antibody target	Manufacturer	Catalog #	Fluorophore	Dilution	RRID
MHCII I-E/A	Tonbo Biosciences	75-5321	V450	1/250	AB_2621965
CD8a	BD Biosciences	560469	V450	1/250	AB_1645281
CD11b	Tonbo Biosciences	35-0112	FITC	1/250	AB_2621676
CD62L	Tonbo Biosciences	35-0621	FITC	1/100	AB_2621697
CD44	Tonbo Biosciences	50-0441	PE	1/5000	AB_2621762
CTLA-4	BD Biosciences	561718	PE	1/250	AB_10895585
CD31	BD Biosciences	561073	PE	1/750	AB_10563931
CD4	Biolegend	100516	APC	1/1000	AB_312719
Ly6C	BD Biosciences	560595	APC	1/500	AB_1727554
FoxP3	eBiosciences	50-5773-82	e660	1/100	AB_11218868
F4/80	eBiosciences	45-4801-82	PerCP-Cy5.5	1/250	AB_914345
CD3e	Tonbo Biosciences	65-0031	PerCP-Cy5.5	1/250	AB_2621872
Ly6G (Gr1)	Tonbo Biosciences	80-5931	rF710	1/1000	AB_2621999
CD8a	Tonbo Biosciences	80-0081	rF710	1/500	AB_2621977
PD-1	BD Biosciences	565815	APC-R700	1/500	AB_2739366
CD45	Biolegend	103109	PE-Cy5	1/5000	AB_312974
CD4	Tonbo Biosciences	55-0041	PE-Cy5	1/2500	AB_2621816
CD69	BD Biosciences	552879	PE-Cy5	1/1000	AB_394508
CD11b	Tonbo Biosciences	55-0112	PE-Cy5	1/5000	AB_2621818
EpCAM	Biolegend	118215	PE-Cy7	1/750	AB_1236477
CD11c	BD Biosciences	561022	PE-Cy7	1/500	AB_2033997
Ly6C	eBiosciences	25-5932-80	PE-Cy7	1/1000	AB_2573502
CD25	Tonbo Biosciences	60-0251	PE-Cy7	1/500	AB_2621843
CD11c	Biolegend	117323	APC-Cy7	1/500	AB_830646
CD45	BD Biosciences	557659	APC-Cy7	1/500	AB_396774

Table 2. Gating strategy used in flow cytometry analysis.

Cell population	Gating strategy
CD8 T cells	CD45+, CD3e+, CD4-, CD8a+
CD4 T cells	CD45+, CD3e+, CD4+, CD8a-
Tregs	CD45+, CD3e+, CD4+, CD8a-, CD25+, FoxP3+
Monocytes	CD45+, CD11b+, Ly6G-, Ly6C+, F4/80-
Macrophages	CD45+, CD11b+, Ly6G-, Ly6C-, F4/80+
Granulocytes	CD45+, CD11b+, Ly6G+, Ly6C-/+, F4/80-
Dendritic cells	CD45+, CD11c+, MHCII+, F4/80-
Endothelial cells	CD45-, GFP-, EpCAM-, CD31+

Figure 1. Ephrin-A1-deficient hosts have reduced metastasis and tumor recurrence but no difference in primary tumor growth. (A) 4T1 primary tumor growth curves in age-matched female *Efna1*^{+/+} (WT) and *Efna1*^{-/-} (KO) mice and resulting tumor weights at day 21 post-implantation. (B) Schematic diagram showing experimental procedure for evaluating spontaneous metastases. (C) 4T1 primary tumor growth curves in WT and KO mice and resultant tumor weights at time of surgical resection on day 14. (D) 4T1 primary tumor growth curves in WT, heterozygous (+/-) and KO littermates and resultant tumor weights at time of surgical resection on day 14. (E) Blinded quantification of visible lung metastases and lung weights from WT and KO mice at experimental endpoint on day 32. (F) Weights of recurrent 4T1 tumor at primary site 18 days after surgical resection. Data shown are averages $\pm$ SD ($n=9-12$ mice per group). * $p<0.05$, ** $p<0.01$ (unpaired Mann-Whitney *U*-test).

primary tumors resected from *Efna1*^{+/+} and *Efna1*^{-/-} mice were not different in size (Figure 1C), and this was additionally verified with *Efna1*^{+/+}, *Efna1*^{+/+}, and *Efna1*^{-/-} littermates (Figure 1D). However, at the experimental endpoint, the number of visible lung metastases and lung weights were significantly decreased in knockout mice (Figure 1E). Many of these mice not only harbored lung metastases but also tumors that had regrown at the original site of the resected primary tumor. Similar to our findings in lung metastases, the size of recurrent primary tumors was significantly reduced in knockout mice (Figure 1F). Together, these results demonstrate that while host deficiency in ephrin-A1 may not affect initial tumor growth, it can impact metastatic spread and recurrence. Underlying data are available^{47,48}.

To complement our findings in our model of spontaneous metastasis, we evaluated the impact of ephrin-A1 host deficiency on experimental metastasis. 4T1 cells engineered to express GFP and luciferase (4T1-GFP-luciferase) were injected into the tail veins of *Efna1*^{+/+}, *Efna1*^{+/+}, and *Efna1*^{-/-} littermates. *In vivo* bioluminescence imaging several hours after injection illustrated comparable signal across all mice (Figure 2A, B), indicating ephrin-A1 host deficiency did not impact tumor cell trafficking and lodging within the lung, at least in this short time frame. After harvesting the lungs 17 days later, we observed decreased GFP+ metastases in *Efna1*^{-/-} mice, compared to both *Efna1*^{+/+} and *Efna1*^{+/+} littermates, which was additionally confirmed by flow cytometry (Figure 2C, D). Similarly, histological analysis revealed fewer metastatic foci in lungs

Figure 2. Ephrin-A1-deficient hosts have reduced cancer cell lung colonization. (A) Representative image of bioluminescence signal in WT and KO littermates several hours after tail vein injection of 1×10^5 4T1-GFP-luciferase cells. (B) Quantification of bioluminescence signal in WT, +/-, and KO littermates. (C) Representative images of GFP+ surface lung metastases in WT and KO littermates 17 days after tail vein injection. (D) Blinded quantification of GFP+ lung metastases in WT, +/-, and KO littermates and percentages of GFP+ 4T1 cells in the lung from flow cytometry analysis. (E) Representative H&E staining of left lung lobes from WT and KO littermates and blinded quantification of metastatic foci per lung section. Scale bar: 200 μ m. Data shown are averages $\pm$ SD ($n=4-9$ mice per group). * $p<0.05$, ** $p<0.01$ (unpaired Mann-Whitney *U*-test for comparisons between two groups, Kruskal-Wallis *H*-test with post-hoc unpaired Mann-Whitney *U*-test for comparisons between three groups).

from *Efnal*^{-/-} mice (Figure 2E). These data align with our previous observations on endogenous metastasis and suggest that host deficiency in ephrin-A1 inhibits circulating cancer cells from colonizing the lung. Underlying data are available^{49,50}.

Tumor-infiltrating immune populations are not significantly different in ephrin-A1-deficient hosts

Ephrin-A1 is expressed in several types of host cells, including immune cells and endothelial cells³⁹⁻⁴¹. Thus, we sought

to determine how the ephrin-A1-deficient host immune system and endothelium may mitigate metastasis. Among immune cells, Ephrin-A1 can be expressed in B and T cells, monocytes, and macrophages³⁹. The role of ephrin-A1 in B cells is largely unknown⁵¹. However, in T cells, monocytes, and macrophages, ephrin-A1 has been shown to regulate cell adhesion and migration^{11,12,15,27,52-55}. These immune cell populations play a critical role in overall anti-tumor immunity and immunosurveillance. Dendritic cells and T cells, particularly CD8 cytotoxic

T cells, are the primary drivers of the adaptive anti-tumor response in solid tumors and increased infiltration of these cell types is correlated with better prognosis and enhanced response to immunotherapies^{56,57}. Conversely, T regulatory cells (Tregs) suppress effector functions of T cells and typically inhibit the anti-tumor response^{58,59}. Between the two ends of this spectrum, myeloid populations, such as monocytes, macrophages, and granulocytes, can either promote or suppress an anti-tumor response, depending on their polarization and functionality^{60,61}.

Because of ephrin-A1's known role in adhesion and chemotaxis of immune cells, we performed flow cytometry analysis on 4T1 primary tumors harvested from *Efnal*^{+/+}, *Efnal*^{+/-}, and *Efnal*^{-/-} littermates. To our surprise, we found no significant differences in total infiltrating immune cells, CD4 or CD8 T cells, dendritic cells, Tregs, or myeloid populations in *Efnal*^{+/+}, *Efnal*^{+/-}, and *Efnal*^{-/-} littermates (Figure 3A, B). While there were no apparent differences in the immune microenvironment of the mammary tumors, the immune microenvironment of the lung is distinct from that of the mammary gland and may

Figure 3. Tumor-infiltrating immune populations are not significantly different in ephrin-A1-deficient hosts. (A) Flow cytometric analysis of total immune cells, T cells, and T regulatory (Treg) cells, as well as (B) monocytes, macrophages, granulocytes, and dendritic cells, in 4T1 primary tumors resected from WT, +/-, and KO littermates at day 14 post-implantation. (C, D) Similar analyses of immune populations in tumor-bearing lungs harvested from WT, +/-, and KO littermates 17 days after tail vein injection of 4T1-GFP-luciferase cells. Data shown are averages $\pm$ SD ($n=3-7$ mice per group). * $p<0.05$ (Kruskal-Wallis H -test with post-hoc unpaired Mann-Whitney U -test).

impact the metastatic niche. To investigate this, we performed flow cytometry analysis on 4T1 tumor-bearing lungs generated from our model of experimental metastasis. Similar to the results we obtained from the 4T1 primary tumors, we did not see significant differences in immune populations in tumor-bearing lungs harvested from *Efnal*^{+/+}, *Efnal*^{+/-}, and *Efnal*^{-/-} littermates, except for a modest increase in macrophages in knockout mice (Figure 3C, D). Underlying data are available^{62,63}.

Although the percentage of tumor infiltrating T cells in *Efnal*^{+/+} and *Efnal*^{-/-} mice is comparable, their activation status and effector function may still be different. Tumor-infiltrating T cells with upregulated expression of activation markers, such as CD44, CD69, and CD25, and downregulated expression of antigen-naïve markers like CD62L and exhaustion markers like PD-1 and CTLA-4 indicate a higher T cell functional status that mediates a stronger and more enduring anti-tumor response^{58,59}. We assessed these markers on T cells in 4T1 primary tumors and tumor-bearing lungs from *Efnal*^{+/+} and *Efnal*^{-/-} littermates using flow cytometry. However, we did not observe consistent increases in activation or decreases in naïve or exhaustion markers in knockout-derived T cells (data not shown, included in Underlying data)⁶². In summary, host deficiency in ephrin-A1 does not significantly affect tumor-infiltrating immune cells in both primary tumors and tumor-bearing lungs. Thus, the reduction of lung metastases in *Efnal*^{-/-} hosts *in vivo* is unlikely due to host immunity.

Tumor vascularity and pericyte coverage are not significantly different in ephrin-A1-deficient hosts

In addition to the anti-tumor immune response, another host factor that can impact metastasis is the tumor vasculature. Angiogenesis is the formation of new blood vessels from a pre-existing network and is required for solid tumor growth and progression. Blood vessels can supply nutrients that support tumor growth and provide an entry for hematological dissemination and invasion^{1,64}. These new blood vessels are typically hastily constructed in response to the high release of growth factors, such as vascular endothelial growth factor (VEGF), from tumor cells^{65,66}. Thus, tumor vessels tend to be disorganized, leaky, and poorly covered by pericytes, which normally support the integrity of the endothelium. Ephrin-A1 is expressed in the vascular endothelium and has been shown to promote angiogenesis *in vitro* and in several *in vivo* models⁶⁷⁻⁷². Therefore, we hypothesized that tumors in *Efnal*^{-/-} mice may have reduced tumor vasculature and increased endothelial pericyte coverage compared to *Efnal*^{+/+} controls.

To evaluate tumor vascularity and vessel function, we co-stained cryosections of 4T1 primary tumors from *Efnal*^{+/+} and *Efnal*^{-/-} littermates with CD31 and α SMA, markers for endothelial cells and pericytes, respectively. Colocalization of α SMA with CD31 acts as an indicator for functional endothelium within tumors. Surprisingly, we did not observe a change in CD31+ area or intensity in 4T1 tumors from *Efnal*^{+/+} and *Efnal*^{-/-} littermates (Figure 4A, B). Furthermore, pericyte

Figure 4. Tumor vascularity and pericyte coverage are not significantly different in ephrin-A1-deficient hosts. (A) Representative images of CD31 (red), α SMA (green), and DAPI (blue) staining on cryosections of 4T1 primary tumors harvested from WT and KO littermates at day 14 post-implantation. Scale bar: 100 μ m. (B) Quantification of CD31+ area and integrated intensity in arbitrary units (au) per high power field (hpf) of view. (C) Quantification of α SMA colocalization with CD31 as a percentage of α SMA+ over CD31+ stained area and integrated density. Data shown are averages $\pm$ SD ($n=3-7$ mice per group).

coverage on tumor vessels remained the same in tumors from *Efnal^{+/+}* and *Efnal^{-/-}* littermates (Figure 4A, C). Together, these data suggest that loss of ephrin-A1 in the host does not affect tumor vessel formation and function in the primary tumor. Underlying data are available⁷³.

Ephrin-A1-deficient lung microenvironment provides a less favorable metastatic niche

Our results from analysis of the immune infiltrate and vasculature of primary tumors, coupled with the significant difference in experimental lung metastasis between *Efnal^{+/+}* and *Efnal^{-/-}* mice, suggest that host factors critical to this metastatic phenotype are more likely to lie downstream of the primary tumor site. These steps include tumor cell trafficking to the lung vasculature, extravasation, and adaptation to new selective pressures of the lung microenvironment. 4T1 cell trafficking to the lung was not significantly different between *Efnal^{+/+}* and *Efnal^{-/-}* littermates after tail vein injections (Figure 2A, B). Thus, we aimed to evaluate extravasation and adaptation to the lung metastatic niche in *Efnal^{+/+}* and *Efnal^{-/-}* hosts.

To test extravasation of 4T1 cells *in vivo*, we injected 4T1-GFP-luciferase cells labeled with CellTrace Violet dye into the tail veins of *Efnal^{+/+}* and *Efnal^{-/-}* littermates. This dye is retained only in the labeled tumor cells and diminished after subsequent cell divisions, enabling quantification of short-term cell proliferation. At 24 hours after injection, we perfused the lungs with PBS to flush out remaining cells in the pulmonary vasculature and processed the lungs for flow cytometry. Decreased GFP+ 4T1 cells were found in ephrin-A1-deficient lungs compared to wild-type controls (Figure 5A), suggesting that fewer cancer cells had extravasated into the lung parenchyma at this timepoint. This result was not due to decreased vascularity of ephrin-A1-deficient lungs at baseline, as CD31+ endothelial cells were not significantly different in knockout and wild-type lungs (Figure 5B). Moreover, this was not due to decreased proliferation of the 4T1 cells within the 24-hour timeframe, as the amount of retained CellTrace Violet dye was not increased in 4T1 cells that had extravasated in knockout lungs compared to wild-type lungs (Figure 5C). Together, these data suggest that extravasation of 4T1 cells is

Figure 5. Ephrin-A1-deficient lung microenvironment provides a less favorable metastatic niche. (A) Quantification of GFP+ 4T1 cells and (B) CD31+ endothelial cells by flow cytometry in perfused lungs harvested from WT and KO littermates 24 hours post-tail vein injection. (C) Percentage of GFP+ 4T1 cells in perfused WT and KO lungs that still contained CellTrace Violet dye, indicating reduced proliferation. (D) Representative images of PCNA staining on FFPE sections of tumor-bearing lungs from WT and KO littermates 17 days after tail vein injection of 4T1-GFP-luciferase cells. Higher magnification images and blinded quantification of PCNA+ tumor cell nuclei shown. Scale bar: 50 μ m. Data shown are averages $\pm$ SD ($n=3-6$ mice per group). * $p<0.05$ (unpaired Mann-Whitney U -test).

inhibited in knockout mice, compared to wild-type controls, and ephrin-A1 deficiency in the host lung may play a role in this process.

While decreased extravasation of tumor cells may explain in part the decreased lung metastases in *Efnal^{-/-}* mice, another possibility is that once tumor cells have extravasated and established in the lung, they have reduced fitness of survival in ephrin-A1-deficient lungs, compared to wild-type lungs. There are many stressors in the lung metastatic niche that could impact the adaptability of the tumor cell. We used tumor proliferation index as a marker to evaluate how well tumor cells have adapted to a metastatic niche. Since no differences were observed in proliferation of 4T1 cells that had newly extravasated into the lung parenchyma of *Efnal^{+/+}* and *Efnal^{-/-}* littermates within the short 24-hour timeframe (Figure 5C), we next assessed proliferation of tumor cells in lung micrometastases that had established over 17 days after tail vein injection (Figure 2). There was a significant decrease in cell proliferation in metastatic foci established in *Efnal^{-/-}* mice, compared to *Efnal^{+/+}* controls, as indicated by PCNA staining (Figure 5D). These findings suggest that reduced tumor cell lung colonization in *Efnal^{-/-}* hosts is due to both decreased extravasation of cancer cells and decreased proliferation in the metastatic niche. Underlying data are available^{74,75}.

Discussion

In conclusion, host deficiency in ephrin-A1 inhibits metastasis by providing a less hospitable metastatic niche for cancer cell extravasation and colonization of the lung. Our data from 4T1 primary tumor specimens demonstrated no differences in primary tumor growth, infiltrating immune cell populations, and vascularity. This led us to investigate the metastatic process downstream from the primary tumors. We then found that lung colonization in knockout mice was decreased compared to wild-type mice as early as 24 hours post-tail vein injection of 4T1 cells, in part due to decreased extravasation. Moreover, the metastases that established in *Efnal^{-/-}* lungs were not only reduced in number but also less proliferative compared to those in wild-type lungs. These studies offer insight on how host expression of ephrin-A1 may impact tumor growth and dissemination, but they also lead to additional questions.

Our ephrin-A1 knockout model is not tissue-specific nor inducible, which creates challenges in identifying specific mechanisms that contribute to our observed phenotype. For example, ephrin-A1 is highly expressed in embryonic stages of development and plays a known role in neuronal and mammary development^{67,76–80}. The transcriptional and epigenetic changes that occur *in utero* and during early physiological development as a result of ephrin-A1 deficiency in various tissues may all contribute to the observed phenotype; however, dissecting which changes are directly downstream of ephrin-A1 and critical to metastasis may be quite difficult. This challenge is further augmented when we consider the many cell types that can express ephrin-A1, especially immune, endothelial, and epithelial cells.

Many studies have demonstrated ephrin-A1's role in immune cell adhesion and migration. Although we did not observe significant differences in tumor immune infiltrate, this does not preclude a role for ephrin-A1 in these cell populations. Immune cells engage in a complex network of crosstalk, and it is possible that loss of ephrin-A1 in one cell type may mask the effects it has in another. One intriguing difference we observed was an increase in macrophages in *Efnal^{-/-}* tumor-bearing lungs. However, we have not determined if this difference occurs in the specific context of a stressor, such as tumor metastasis, or if knockout mice have increased macrophages at baseline. Furthermore, it remains to be seen if these macrophages are polarized towards an anti-tumor or a pro-tumor response. Nevertheless, this offers evidence of a novel role of ephrin-A1 in macrophage differentiation or survival, which requires further investigation.

In addition, ephrin-A1 has been shown to regulate expression of adhesion molecules on endothelial cells and promote angiogenesis. Modulation of surface expression of adhesion proteins, such as ICAM-1 and VCAM-1, on endothelial cells impact binding to immune cells and cancer cells^{8,40}. Thus, it is possible that ephrin-A1 on endothelial cells may mediate cancer cell transendothelial migration through modulation of these adhesion proteins. While this result may be consistent with published literature, in contrast to ephrin-A1's known role in angiogenesis, we did not observe differences in angiogenesis between tumors from *Efnal^{+/+}* and *Efnal^{-/-}* hosts. This discrepancy may be due to a couple reasons. First, most studies reporting on ephrin-A1's impact on angiogenesis has shown its effect through EphA receptor signaling on the endothelial cell, not necessarily through ephrin-A1 directly in the endothelium^{67–70}. Loss of ephrin-A1 in the endothelium and other host tissues is unlikely to completely abrogate EphA receptor signaling in the endothelium, as other ephrin ligands are able to promiscuously bind to the same EphA receptors and may even compensate for the loss of ephrin-A1³⁷. Second, some of these studies use soluble ephrin-A1, instead of membrane-bound or cell-surface ephrin-A1. In our *Efnal^{-/-}* model, both cell-surface, membrane-bound ephrin-A1 and soluble, secreted ephrin-A1 are lost *in vivo*, and these two forms of ephrin-A1 have been shown to have competing effects¹³.

The different forms of ephrin-A1, as well as the range of interactions with various Eph receptors, show how potentially complex the molecular mechanisms can be when considering host deficiency of ephrin-A1. A clue into this complicated investigation can be found in our data obtained with ephrin-A1 heterozygote controls. When comparing tumor metastasis and immune infiltrate, results from *Efnal^{+/-}* mice were much more comparable to wild-type than knockout littermate controls. This suggests that ephrin-A1 has a genetically dominant effect – one wild-type allele may be sufficient to induce the wild-type phenotype.

Although we focused our inquiries on primary mammary tumors and lung metastases, there is much more to be explored. 4T1

cells, like human breast cancer, metastasize to other organ sites, such as the bone, liver, and brain. The lungs in *Efnal^{-/-}* hosts may or may not be the only organ that provides a less favorable environment for colonizing tumor cells than those in *Efnal^{+/+}* hosts. We observed differences in recurrent primary tumor, in addition to lung metastases, which may indicate that tumor cell apoptosis or senescence is altered in knockout hosts. Further elucidating the mechanisms by which ephrin-A1 host deficiency limits cancer relapse and metastasis may enhance our understanding of the metastatic process and ultimately shed new light on novel therapeutic strategies.

Data availability

Underlying data

Harvard Dataverse: Host deficiency in ephrin-A1 inhibits breast cancer metastasis; <https://dataverse.harvard.edu/dataverse/hostEfnal1metastasis>.

This project contains the following underlying data:

Harvard Dataverse: 4T1 primary tumor dimensions and weights. <https://doi.org/10.7910/DVN/AGKDWV>⁴⁷. (4T1 primary tumor dimensions from digital caliper measurements, volume calculations, and weights (related to Figure 1A, C, D).)

Harvard Dataverse: 4T1 recurrent primary and spontaneous lung metastases. <https://doi.org/10.7910/DVN/FU8JEY>⁴⁸. (Spontaneous 4T1 lung metastases quantification and recurrent primary tumor weights (related to Figure 1E, F).)

Harvard Dataverse: Images and quantification of 4T1-GFP-luciferase experimental lung metastases. <https://doi.org/10.7910/DVN/2ANDYX>⁴⁹. (Experimental 4T1-GFP-luciferase lung metastases quantification and images (related to Figure 2C-E).)

Harvard Dataverse: 4T1-GFP-luciferase bioluminescence images and quantification post-tail vein injection. <https://doi.org/10.7910/DVN/39DOYR>⁵⁰. (4T1-GFP-luciferase bioluminescence quantification and images (related to Figure 2A, B).)

Harvard Dataverse: 4T1 primary tumor flow cytometry. <https://doi.org/10.7910/DVN/ZRX2RG>⁶². (Flow cytometry files (fcs), gating and analysis (wsp), and panels (xlsx) containing immune profiling of 4T1 primary mammary tumors from *Efnal^{+/+}*, *Efnal^{+/-}*, and *Efnal^{-/-}* littermate mice (related to Figure 3A, B).)

Harvard Dataverse: 4T1-GFP-luciferase tumor-bearing lung flow cytometry. <https://doi.org/10.7910/DVN/S06NQ1>⁶³. (Flow cytometry files (fcs), gating and analysis (wsp), and panels (xlsx) containing immune profiling of 4T1-GFP-luciferase tumor-bearing lungs from *Efnal^{+/+}*, *Efnal^{+/-}*, and *Efnal^{-/-}* littermate mice (related to Figure 2D, 3C, D).)

Harvard Dataverse: 4T1-GFP-luciferase 24-hr lung colonization flow cytometry. <https://doi.org/10.7910/DVN/G7TAAE>⁷⁴. (Flow cytometry files (fcs), gating and analysis (wsp), and panels (xlsx) containing profiling of 24-hr 4T1-GFP-luciferase tail vein injected lungs from *Efnal^{+/+}* and *Efnal^{-/-}* littermate mice (related to Figure 5A-C).)

Harvard Dataverse: CD31 and aSMA images and quantification of 4T1 primary tumors. <https://doi.org/10.7910/DVN/MOYPE7>⁷³. (4T1 primary tumor CD31 and αSMA staining quantification and images (related to Figure 4A-C).)

Harvard Dataverse: PCNA images and quantification of 4T1-GFP-luciferase lung metastases. <https://doi.org/10.7910/DVN/8AJKFM>⁷⁵. (Lung metastasis PCNA staining quantification and images (related to Figure 5D).)

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

Acknowledgements

Sample preparation was supported by the Vanderbilt Translational Pathology Shared Resource and Brain Institute. We also thank the Vanderbilt Center for Small Animal Imaging and Flow Cytometry Shared Resource for their assistance.

References

- Folkman J: **Angiogenesis: an organizing principle for drug discovery?** *Nat Rev Drug Discov.* 2007; 6(4): 273–286.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ferrara N, Hillan KJ, Gerber HP, et al.: **Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.** *Nat Rev Drug Discov.* 2004; 3(5): 391–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zou W, Chen L: **Inhibitory B7-family molecules in the tumour microenvironment.** *Nat Rev Immunol.* 2008; 8(6): 467–477.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pardoll DM: **The blockade of immune checkpoints in cancer immunotherapy.** *Nat Rev Cancer.* 2012; 12(4): 252–264.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chiang AC, Massagué J: **Molecular basis of metastasis.** *N Engl J Med.* 2008; 359(26): 2814–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Weigelt B, Peterse JL, Van't Veer LJ: **Breast cancer metastasis: markers and models.** *Nat Rev Cancer.* 2005; 5(8): 591–602.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chaffer CL, Weinberg RA: **A perspective on cancer cell metastasis.** *Science.* 2011; 331(6024): 1559–1564.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Strlic B, Offermanns S: **Intravascular Survival and Extravasation of Tumor Cells.** *Cancer Cell.* 2017; 32(3): 282–293.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fujii H, Tatsumi K, Kosaka K, et al.: **Eph-ephrin A system regulates murine blastocyst attachment and spreading.** *Dev Dyn.* 2006; 235(12): 3250–3258.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Moon JJ, Lee SH, West JL: **Synthetic biomimetic hydrogels incorporated with ephrin-A1 for therapeutic angiogenesis.** *Biomacromolecules.* 2007; 8(1): 42–49.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ende G, Poitz DM, Wiedemann E, et al.: **TNF-α-mediated adhesion of monocytes**

- to endothelial cells-The role of ephrinA1. *J Mol Cell Cardiol.* 2014; 77: 125–135.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Saeki N, Nishino S, Shimizu T, *et al.*: EphA2 promotes cell adhesion and spreading of monocyte and monocyte/macrophage cell lines on integrin ligand-coated surfaces. *Cell Adhes Migr.* 2015; 9(6): 469–482.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 13. Yu M, Wang J, Muller DJ, *et al.*: In PC3 prostate cancer cells ephrin receptors crosstalk to β 1-integrins to strengthen adhesion to collagen type I. *Sci Rep.* 2015; 5: 8206.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Lim W, Bae H, Bazer FW, *et al.*: Functional Roles of Eph A-Ephrin A1 System in Endometrial Luminal Epithelial Cells During Early Pregnancy. *J Cell Physiol.* 2017; 232(6): 1527–1538.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Mukai M, Suruga N, Saeki N, *et al.*: EphA receptors and ephrin-A ligands are upregulated by monocytic differentiation/maturation and promote cell adhesion and protrusion formation in HL60 monocytes. *BMC Cell Biol.* 2017; 18(1): 28.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 16. Daoud A, Gopal U, Kaur J, *et al.*: Molecular and functional crosstalk between extracellular Hsp90 and ephrin A1 signaling. *Oncotarget.* 2017; 8(63): 106807–106819.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 17. Kaplan N, Ventrella R, Peng H, *et al.*: EphA2/Ephrin-A1 Mediate Corneal Epithelial Cell Compartmentalization via ADAM10 Regulation of EGFR Signaling. *Investig Ophthalmol Vis Sci.* 2018; 59(1): 393–406.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 18. Funk SD, Finney AC, Yurdagül A Jr, *et al.*: EphA2 stimulates VCAM-1 expression through calcium-dependent NFAT1 activity. *Cell Signal.* 2018; 49: 30–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 19. Valenzuela JI, Perez F: Localized Intercellular Transfer of Ephrin-As by Trans-endocytosis Enables Long-Term Signaling. *Dev Cell.* 2020; 52(1): 104–117.e5.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Miao H, Li DQ, Mukherjee A, *et al.*: EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. *Cancer Cell.* 2009; 16(1): 9–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Parri M, Buricchi F, Giannoni E, *et al.*: EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to rho-dependent actin/myosin contractility. *J Biol Chem.* 2007; 282(27): 19619–19628.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Hjorthaug HS, Aasheim H-C: Ephrin-A1 stimulates migration of CD8⁺CCR7⁺ T lymphocytes. *Eur J Immunol.* 2007; 37(8): 2326–2336.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Woo S, Rowan DJ, Gomez TM: Retinotopic Mapping Requires Focal Adhesion Kinase-Mediated Regulation of Growth Cone Adhesion. *J Neurosci.* 2009; 29(44): 13981–13991.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Lin S, Gordon K, Kaplan N, *et al.*: Ligand Targeting of EphA2 Enhances Keratinocyte Adhesion and Differentiation via Desmoglein 1. *Mol Biol Cell.* 2010; 21(22): 3902–3914.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Yang NY, Fernandez C, Richter M, *et al.*: Crosstalk of the EphA2 Receptor with a Serine/Threonine Phosphatase Suppresses the Akt-mTORC1 Pathway in Cancer Cells. *Cell Signal.* 2011; 23(1): 201–212.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Sukka-Ganesh B, Mohammed KA, Kaye F, *et al.*: Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene. *BMC Cancer.* 2012; 12: 309.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Jellinghaus S, Poitz DM, Ende G, *et al.*: Ephrin-A1/EphA4-mediated adhesion of monocytes to endothelial cells. *Biochim Biophys Acta - Mol Cell Res.* 2013; 1833(10): 2201–2211.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Ieguchi K, Tomita T, Omori T, *et al.*: ADAM12-cleaved ephrin-A1 Contributes to Lung Metastasis. *Oncogene.* 2014; 33(17): 2179–2190.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. Brantley-Sieders DM, Jiang A, Sarma K, *et al.*: Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. *PLoS One.* 2011; 6(9): e24426.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 30. Ieguchi K, Omori T, Komatsu A, *et al.*: Ephrin-A1 expression induced by S100A8 is mediated by the toll-like receptor 4. *Biochem Biophys Res Commun.* 2013; 440(4): 623–629.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Youngblood VM, Kim LC, Edwards DN, *et al.*: The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. *Cancer Res.* 2016; 76(7): 1825–1836.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. Efazat G, Novak M, Kaminsky VO, *et al.*: Ephrin B3 interacts with multiple EphA receptors and drives migration and invasion in non-small cell lung cancer. *Oncotarget.* 2016; 7(37): 60332–60347.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 33. Chu M, Zhang C: Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer. *Sci Rep.* 2018; 8(1): 1539.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 34. Zhuo W, Liu Y, Li S, *et al.*: Long Noncoding RNA *GMAN*, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding *GMAN-AS*. *Gastroenterology.* 2019; 156(3): 676–691.e11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Lee PC, Chen ST, Kuo TC, *et al.*: C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. *Oncogene.* 2020; 1–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Lisabeth EM, Falivelli G, Pasquale EB: Eph receptor signaling and ephrins. *Cold Spring Harb Perspect Biol.* 2013; 5(9): pii: a009159.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 37. Kania A, Klein R: Mechanisms of ephrin-Eph signalling in development, physiology and disease. *Nat Rev Mol Cell Biol.* 2016; 17(4): 240–256.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Barquilla A, Pasquale EB: Eph receptors and ephrins: therapeutic opportunities. *Annu Rev Pharmacol Toxicol.* 2015; 55: 465–487.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 39. Darling TK, Lamb TJ: Emerging Roles for Eph Receptors and Ephrin Ligands in Immunity. *Front Immunol.* 2019; 10: 1473.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Shiu E, Chen J: Eph Receptor Tyrosine Kinases in Tumor Immunity. *Cancer Res.* 2016; 76(22): 6452–6457.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Coulthard MG, Morgan M, Woodruff TM, *et al.*: Eph/ephrin signaling in injury and inflammation. *Am J Pathol.* 2012; 181(5): 1493–1503.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Liu DP, Wang Y, Koeffler HP, *et al.*: Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. *Int J Oncol.* 2007; 30(4): 865–871.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Zhang W, Zeng X, Briggs KJ, *et al.*: A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. *Oncogene.* 2010; 29: 2467–2476.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 44. Frieden LA, Townsend TA, Vaught DB, *et al.*: Regulation of heart valve morphogenesis by Eph receptor ligand, ephrin-A1. *Dev Dyn.* 2010; 239(12): 3226–3234.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Brantley-Sieders DM, Zhuang G, Vaught D, *et al.*: Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis *in vivo*. *Mol Cancer Res.* 2009; 7(5): 615–623.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Varghese F, Bukhari AB, Malhotra R, *et al.*: IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. *PLoS One.* 2014; 9(5): e96801.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Shiu E: “4T1 primary tumor dimensions and weights”. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/AGKDWV>
 48. Shiu E: “4T1 recurrent primary and spontaneous lung metastases”. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/FU8JEY>
 49. Shiu E: “Images and quantification of 4T1-GFP-luciferase experimental lung metastases”. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/2ANDYX>
 50. Shiu E: “4T1-GFP-luciferase bioluminescence images and quantification post-tail vein injection”. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/39D0YR>
 51. Alonso-C LM, Trinidad Eva MA, de Garcillan B, *et al.*: Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells. *Leuk Res.* 2009; 33(3): 395–406.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Wohlfahrt JG, Karagiannis C, Kunzmann S, *et al.*: Ephrin-A1 suppresses Th2 cell activation and provides a regulatory link to lung epithelial cells. *J Immunol.* 2004; 172(2): 843–850.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. Sharfe N, Nikolic M, Cimpean L, *et al.*: EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. *Mol Immunol.* 2008; 45(5): 1208–1220.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Aasheim HC, Delabie J, Finne EF: Ephrin-A1 binding to CD4⁺ T lymphocytes stimulates migration and induces tyrosine phosphorylation of PYK2. *Blood.* 2005; 105(7): 2869–76.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Sharfe N, Freywald A, Toro A, *et al.*: Ephrin stimulation modulates T cell chemotaxis. *Eur J Immunol.* 2002; 32(12): 3745–3755.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle.

- Immunity*. 2013; **39**(1): 1–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Binnewies M, Roberts EW, Kersten K: **Understanding the tumor immune microenvironment (TIME) for effective therapy**. *Nat Med*. 2018; **24**(5): 541–550.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Jiang Y, Li Y, Zhu B: **T-cell exhaustion in the tumor microenvironment**. *Cell Death Dis*. 2015; **6**: e1792–e1792.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Pauken KE, Wherry EJ: **Overcoming T cell exhaustion in infection and cancer**. *Trends Immunol*. 2015; **36**(4): 265–276.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Gabrilovich DI, Nagaraj S: **Myeloid-derived suppressor cells as regulators of the immune system**. *Nat Rev Immunol*. 2009; **9**(3): 162–174.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Awad RM, De Vlaeminck Y, Maebe J, *et al*: **Turn Back the TIME: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression**. *Front Immunol*. 2018; **9**: 1977.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Shiuan E: **“4T1 primary tumor flow cytometry”**. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/ZRX2RG>
 63. Shiuan E: **“4T1-GFP-luciferase tumor-bearing lung flow cytometry”**. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/S06NQ1>
 64. Potente M, Gerhardt H, Carmeliet P: **Basic and therapeutic aspects of angiogenesis**. *Cell*. 2011; **146**(6): 873–887.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Baluk P, Hashizume H, McDonald DM: **Cellular abnormalities of blood vessels as targets in cancer**. *Curr Opin Genet Dev*. 2005; **15**(1): 102–111.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Nagy JA, Chang SH, Shih SC, *et al*: **Heterogeneity of the tumor vasculature**. *Semin Thromb Hemost*. 2010; **36**(3): 321–331.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Ogawa K, Pasqualini R, Lindberg RA, *et al*: **The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization**. *Oncogene*. 2000; **19**(52): 6043–6052.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Brantley DM, Cheng N, Thompson EJ, *et al*: **Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo**. *Oncogene*. 2002; **21**(46): 7011–7026.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Brantley-Sieders DM, Fang WB, Hicks DJ, *et al*: **Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression**. *FASEB J*. 2005; **19**(13): 1884–1886.
[PubMed Abstract](#) | [Publisher Full Text](#)
 70. Chen J, Hicks D, Brantley-Sieders D, *et al*: **Inhibition of retinal neovascularization by soluble EphA2 receptor**. *Exp Eye Res*. 2006; **82**(4): 664–673.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Brantley-Sieders DM, Fang WB, Hwang Y, *et al*: **Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice**. *Cancer Res*. 2006; **66**(21): 10315–10324.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. Dunaway CM, Hwang Y, Lindsley CW, *et al*: **Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis**. *Mol Cell Biol*. 2011; **31**(3): 404–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Shiuan E: **“CD31 and aSMA images and quantification of 4T1 primary tumors”**. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/MOYPE7>
 74. Shiuan E: **“4T1-GFP-luciferase 24-hr lung colonization flow cytometry”**. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/G7TAAE>
 75. Shiuan E: **“PCNA images and quantification of 4T1-GFP-luciferase lung metastases”**. Harvard Dataverse, V1. 2020.
<http://www.doi.org/10.7910/DVN/8AJKFM>
 76. Vaught D, Chen J, Brantley-Sieders DM: **Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase**. *Mol Biol Cell*. 2009; **20**(10): 2572–2581.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Kang M, Jeong W, Bae H, *et al*: **Bifunctional role of ephrin A1-Eph system in stimulating cell proliferation and protecting cells from cell death through the attenuation of ER stress and inflammatory responses in bovine mammary epithelial cells**. *J Cell Physiol*. 2018; **233**(3): 2560–2571.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. Averaimo S, Assali A, Ros O, *et al*: **A plasma membrane microdomain compartmentalizes ephrin-generated cAMP signals to prune developing retinal axon arbors**. *Nat Commun*. 2016; **7**: 12896.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 79. Harboe M, Torvund-Jensen J, Kjaer-Sorensen K, *et al*: **Ephrin-A1-EphA4 signaling negatively regulates myelination in the central nervous system**. *Glia*. 2018; **66**(5): 934–950.
[PubMed Abstract](#) | [Publisher Full Text](#)
 80. Aoki M, Yamashita T, Tohyama M: **EphA receptors direct the differentiation of mammalian neural precursor cells through a mitogen-activated protein kinase-dependent pathway**. *J Biol Chem*. 2004; **279**(31): 32643–32650.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 22 April 2020

<https://doi.org/10.5256/f1000research.25051.r61807>

© 2020 Cheng N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nikki Cheng

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center (KUMC), Kansas City, KS, USA

EphrinA1 is a cell surface bound protein that has been shown to be tumor suppressive when expressed in cancer cells. In this study, the authors characterize the effects of the microenvironment on mammary tumor progression using variations of the 4T1 mammary tumor model- spontaneous, and experimental metastasis. By injecting 4T1 cells in ephrinA1 knockout mice, they show that ephrinA1 knockout does not affect primary tumor growth and inhibits metastasis and recurrence. The study is generally well written, and the phenotypes are interesting. Comments are described below:

1. The discussion could be better expanded.
2. How do expression of ephrinA1 and corresponding receptors in the stroma of primary tumor vs. lung tissue compare in normal and tumor bearing mice? How do results fit into the bigger picture of what is known about this?
3. Recommend expanding on the discussion of the mechanism regarding ephrinA1 mediated lung metastasis. In particular:
 - a) How might ephrinA1 signaling affect macrophage function in the lung.
 - b) Please expand on what is known about macrophage polarization, effects on T cells in the lung. How would ephrinA1 signaling affect macrophage function in the formation of pre-metastatic vs. metastatic niche?
 - c) How would ephrinA1 ko affect Eph receptorA1 vs. A2 signaling in the lung stroma?
 - d) Further discussion the clinical implications of the study would be helpful, especially since the tumor suppressive/oncogenic effects of ephrinA1 appear to be cell type dependent.

More minor comments:

1. Figure 1A, C, D, Figure 3, Figure 4, Figure 5B-C: Statistics are not consistently shown. Even if data show no statistical significance, it would be helpful to include p- value or indicate n.s to indicate the analysis was done.

2. Figure 4: CO-IF staining is a bit difficult to see. It would be helpful to show magnified insets for clearer details.
3. Figure 5: recommend revising figure legend. From the way the figure legend is stated "**Ephrin-A1-deficient lung microenvironment provides a less favorable metastatic niche**," I would expect data correlating decreased metastasis with changes in the lung microenvironment of ephrinA1 KO mice. However, this is not the case - no changes in endothelial cells were observed. Alternatively, for Figures 3 and 5 - recommend reorganizing some of the data so that the messages are clearer. Figure 3 figure legend indicates that "**Tumor-infiltrating immune populations are not significantly different in ephrin-A1-deficient hosts**" However, Figure 3D show increased in macrophage recruitment to lung tissues in ephrinA1 KO mice. This data would be more appropriate in Figure 5, which shows decreased lung metastasis, along with characterization of endothelial cells in the lung.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No source data required

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 07 May 2020

Eileen Eileen

Thank you for reviewing this manuscript! We have addressed your suggestions and comments with the following revisions:

- 1) Expanded discussion on potential impact of ephrin-A1 deficiency on other ephrin-A1

ligands and EphA receptors in stromal cells and their signaling.

2) Expanded discussion on what is known about the role of macrophages in the lung metastatic niche and how ephrin-A1 deficiency may impact recruitment and function of macrophages.

3) Expanded discussion of clinical implications of the study.

4) Indicated "ns" on graphs where data from WT and KO showed a trending difference that was not statistically significant.

5) Minor text changes.

Competing Interests: No competing interests were disclosed.

Reviewer Report 15 April 2020

<https://doi.org/10.5256/f1000research.25051.r61809>

© 2020 Pasquale E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Elena B. Pasquale

Tumor Initiation and Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA

This is a novel and interesting study on the role of ephrin-A1 expressed in the host in breast cancer lung metastasis. The role of ephrin-A1 in the tumor microenvironment and the metastatic niche is poorly understood. This manuscript addresses this gap in knowledge by systematically investigating how ephrin-A1 expressed in tumor immune cells, the tumor vasculature, the lung vasculature and the lung microenvironment affects lung metastases formed by 4T1 mouse breast cancer cells. These studies uncover a new role of host ephrin-A1 in promoting the formation of lung metastases by breast cancer cells and in tumor recurrence.

Overall, the manuscript is of high quality and most conclusions are well supported by the data presented. I only have several suggestions that the authors might want to consider.

The authors conclude that host ephrin-A1 does not affect the growth of the primary tumor. In contrast, they find that ephrin-A1 present in the microenvironment promotes primary tumor recurrence as well as the growth of lung metastases. However, the primary tumors were seeded by injecting tumor cells mixed with Matrigel. I wonder whether the use of Matrigel might create an artificial microenvironment that obfuscates possible effects of host ephrin-A1 on the primary tumor, particularly at early stages of tumor development. The authors should indicate in the Methods the volume of Matrigel used and mention also in the Results that the tumor cells were

injected mixed with Matrigel. They could also briefly mention in the text the possible effects of Matrigel on primary tumor development (or discuss why they believe using Matrigel is not a significant issue).

In some instances (such as Fig. 3A, dendritic cells panel, and possibly Fig. 5B) the authors find that there is no statistically significant difference between mice with different genotypes. However, n (presumably indicating the number of mice) is small in some groups and the variability of the data is high, so it could be argued that analysis of more mice could yield a more definitive result. Perhaps the conclusions could be stated more cautiously in these cases.

On page 3, left column, third paragraph, ref. 43 does not report a tumor suppressive role of ephrin-A1 but rather the opposite.

Very minor points:

- Animal models section in the Methods: In a couple of sentences, it would seem better to say “female littermates” rather than “gender-matched littermates” since only females were used.
- Specify in the figure legends for the histograms whether the dots represent the number of mice.
- Page 10, right column, 3 lines from the bottom. “Higher” would be better than “increased”.
- Page 11, right column, second paragraph, line 13. It should be “have” not “has”.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Signal transduction, with focus on Eph receptors and ephrins in cancer and

the nervous system.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 07 May 2020

Eileen Eileen

Thank you for reviewing this manuscript! We have addressed your suggestions and comments with the following revisions:

- 1) Added details regarding use of Matrigel in the Methods and Results and discussed potential confounding effects of Matrigel on primary tumor volume in the Discussion.
- 2) For data with small sample sizes showing a nonsignificant trend, revised interpretation of data to include possibility of significant differences if more mice were used.
- 3) Indicated in all figure legends that each data point corresponds to an individual mouse.
- 4) Minor text changes.

Competing Interests: No competing interests were disclosed.

Reviewer Report 07 April 2020

<https://doi.org/10.5256/f1000research.25051.r61805>

© 2020 Yang J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jinming Yang

Department of Cancer Biology and Toxicology, College of Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA

The role of the ephrin-A1/EphA2 signaling axis in tumor cells has been studied extensively. However, many cell types in the tumor microenvironment also express ephrin/Eph molecules, the functions of which are not completely understood. This report investigates the EphA2/ephrin-A1 axis-mediated host-tumor interaction. By implanting tumors in wild-type or ephrin-A1 knockout hosts, the authors showed that loss of ephrin-A1 in tumor microenvironment significantly reduced tumor metastasis, both in the spontaneous allograft model and in experimental metastasis assays via tail vein injection.

Overall, the studies are well designed and the manuscript is well written. Using both spontaneous metastasis and tail vein injection models increases the rigor and reproducibility of the studies.

Experiments are also well controlled by using littermates and scoring blindly. The authors showed negative findings in tumor-infiltrating immune populations and tumor vascularity between ephrin-A1 knockout and wild-type control littermates. Nevertheless, the exact molecular mechanism of ephrin-A1 in tumor metastasis has not been determined. For example, decreased lung metastatic lesions could be due to reduced survival of tumor cells in circulation, extravasation into lung, or growth in the lung microenvironment, as ephrin-A1 is expressed in the lung epithelium, vascular endothelial cells, and some of immune cells. Because this is a global knockout, dissecting specific roles of ephrin-A1 in each cell population in the tumor microenvironment are challenging. After all, the fact that ephrin-A1 plays a critical role in metastasis should be of interest to the general audience in the field of cancer research.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 07 May 2020

Eileen Eileen

Thank you for reviewing this manuscript!

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research